Tukysa ( tucatinib)

pCPA File Number: 21661
Negotiation Status:
Under consideration for negotiation
Indication(s):
Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination
Sponsor/Manufacturer:
Seagen Canada Inc.
CADTH Project Number:
PC0243-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable